- Cancer immunotherapy is a key method in cancer treatment by activating the immune system.
- The PD-1/PD-L1 pathway in the tumor microenvironment promotes tumor immune escape by impairing T cell responses.
- Blocking PD-1/PD-L1 enhances antitumor immune response and improves therapeutic outcomes.
- Anti-PD-1/PD-L1 antibodies have shown significant antitumor effects in clinical practice.
- New strategies targeting PD-1/PD-L1 regulatory mechanisms can reverse tumor immunosuppressive microenvironment.
- Recent studies highlight the fine regulation of the PD-1/PD-L1 pathway in the tumor microenvironment.